Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
 
Approvals Action
First threat to $60m Velcade
Potential generic competition for Janssen's cancer treatment Velcade, worth close to $60 million a year in PBS earnings, has appeared on the drugs register.
Special Report
What next for regulation
The report into medicines regulation has been released, to a largely positive response, but with stakeholder forums taking place next week, industry is waiting to see what will be adopted.
Open Forum
Crestor case to set new threshold
When the High Court hands down its decision in the Crestor case, it is expected to clarify assessment of the obviousness of a method of treatment, write Rebecca Currey and Jane Owen of law firm Bird & Bird.
Pipeline Monitor
New drug class approvals come fast
Amgen scores first in new PCSK9 lipid lowerers, PD-1 inhibitor expands, plus BMS's new HIV combo.
Working Life
How to thrive in a candidates' market
According to the latest report from recruiter Hays, there is a shortage of candidates in pharma at the moment. So, how can you take advantage?